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Sir,
Pseudomonas aeruginosa is the predominant bacterial pathogen in
cystic fibrosis (CF) patients and is associated with decline in
pulmonary function.1 Due to the chronic persistent nature of infec-
tions, CF patients receive frequent antibiotic courses for eradication
of potential pathogens, treatment of acute infective exacerbations
and as chronic suppressive therapy. Consequently, resistance to
antipseudomonal b-lactams is common in the strains collected
from CF patients,2,3 narrowing therapeutic options. Clinicians are
therefore forced to use aminoglycosides or polymyxins, increasing
the risk of adverse effects.4,5 Therefore, optimizing the activity of
b-lactams may help to alleviate this burden. Ceftazidime is a well-
established cephalosporin (on theWHO List of Essential Medicines)
with an excellent safety profile and an antibacterial spectrum that
includes P. aeruginosa. However, ceftazidime is degraded by many
b-lactamases, including ESBLs (Ambler classes A and D), cephalos-
porinases (Ambler class C) and carbapenemases. Avibactam
(formerly NXL-104) is a novel non-b-lactam, broad-spectrum
b-lactamase inhibitor, with promising inhibitory activity against
Ambler class A (including ESBLs and Klebsiella pneumoniae carba-
penemases), C and D b-lactamases.6 Combined with ceftazidime,
it is currently in Phase III clinical trials for the treatment of
complicated intra-abdominal infections, urinary tract infections
and healthcare-associated pneumonia (http://clinicaltrials.
gov identifiers NCT01499290, NCT01500239, NCT01726023,
NCT01644643, NCT01595438 and NCT01808092). In P. aeruginosa
from non-CF patients, avibactam has been shown to reverse ceft-
azidime resistance, bringing MICs to values lower than the EUCAST
and CLSI breakpoints.7,8 However, very little is known about the
effect of avibactam on ceftazidime activity in P. aeruginosa
isolated from CF patients.9 We therefore assembled a collection
of 334 non-duplicate P. aeruginosa isolates from 156 patients
with a clinically confirmed diagnosis of CF equally distributed
between four European countries with a predominance of recent
isolates [Belgium (2010), France (1996–2012), Germany (2012)
and the UK (2006–09)] and used them to assess the activity of cef-
tazidime alone or combined with avibactam. MICs were deter-
mined by microdilution in cation-adjusted Mueller–Hinton broth
following the CLSI methodology for ceftazidime alone (procured
as Glazidimw, the commercial product registered in Belgium
for parenteral use; potency, 88.2%; GlaxoSmithKline; Genval,
Belgium) and combined with 4 mg/L avibactam (NXL-104, potency
91.7%, batch number AFCH005151; AstraZeneca Pharmaceuticals,
Waltham, MA, USA). P. aeruginosa ATCC 27853 (fully susceptible)
and K. pneumoniae ATCC 700603 (resistant to ceftazidime by
the production of SHV-18 b-lactamase) were used as quality con-
trols. Correlations between MICs of ceftazidime and ceftazidime/
avibactam for individual strainswere assessed using quantile dens-
ity contour analysis (JMPw version 10.0.2, SAS Institute Inc., Cary,
NC, USA). Figure 1(a) shows that isolates in this collection had
a high MIC90 of ceftazidime (512 mg/L), with only 36% being
clinically susceptible (MIC ≤8 mg/L) according to EUCAST or
CLSI interpretive criteria. When combined with avibactam, the pro-
portion of susceptible strains increased to 76% and the MIC90
decreased to 64 mg/L. Figure 1(b) shows the fold reduction in
MIC observed in the presence of avibactam for these isolates
classified according to the MIC of ceftazidime. While the mean
reduction in MIC observed for the whole collection was 2.6 dilu-
tions, the amplitude of the effect was clearly dependent on the
initial ceftazidime MIC. Thus, when combined with avibactam,
the MICof ceftazidime decreased by 0.6 dilutions for each doubling
of ceftazidime MIC in the 1–128 mg/L range (0.6 is the slope value
of a linear regression relating the log2MICof the combination to the
log2 MIC of ceftazidime in that range; R
2¼0.965), which would
decrease the MIC to 8–16 mg/L, irrespective of the ceftazidime
MIC in that range of concentrations. For more-resistant strains,
the amplitude of the avibactam effect plateaued at a reduction
of 4 dilutions in MIC for strains for which the ceftazidime MIC
was 256 mg/L and decreased to a reduction of 3 dilutions for
isolates for which the MICs were still higher. This shift in MIC is
illustrated for individual strains in Figure 1(c), which shows the cor-
relation between MICs of individual isolates for ceftazidime alone
and ceftazidime combined with avibactam. Susceptibility to cef-
tazidime was restored in 40% of the strains, with avibactam prov-
ing more effective for strains for which the MIC was ,256 mg/L.
In accordance with the conclusion drawn from Figure 1(c), the cef-
tazidime MIC was now only 4–8 mg/L for most of the affected
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strains, a value that is below the EUCAST and CLSI susceptibility
breakpoints, extending to CF P. aeruginosa isolates the conclusions
obtained for pseudomonal isolates of other origins7 and for other
Gram-negative bacteria.8
Taken together, these data highlight the potential utility of
combining ceftazidime with avibactam for the treatment of
P. aeruginosa infections, including in clinical situations where
resistance rates are high. It also shows that a concentration
of 4 mg/L is sufficient to bring into the susceptible range those
P. aeruginosa strains with a ceftazidime MIC ≤256 mg/L.
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Figure 1. Effect of avibactam (4 mg/L) on the activity of ceftazidime against 334 isolates of P. aeruginosa collected from CF patients. (a) Cumulative MIC
distributionwith indication of MIC50, MIC90 and percentage susceptibility according to the interpretive criteria of EUCAST (susceptible,≤8 mg/L; resistant,
.8 mg/L) and CLSI (susceptible,≤8 mg/L; resistant,≥32 mg/L). The broken line indicates the limit between susceptible and resistant strains according to
EUCAST. (b) Reduction in the MIC (+SD) of ceftazidime (expressed as the number of dilutions) when combined with avibactam as a function of the
ceftazidime MIC. The data were used to fit a log Gaussian equation (R2¼0.979) allowing us to calculate that the maximum amplitude of change
(number of dilutions, 4.3+0.14) occurred at an MIC of 229+29 mg/L. (c) Correlation between MICs of ceftazidime alone (abcissa) and ceftazidime/
avibactam (ordinate) for each individual strain in the collection using quantile density contour analysis. The intensity of each zone (from deep black
to light grey) is indicative of the proportion of strains (from large to small) with MICs at the corresponding coordinates. The broken lines point to the
MIC value above which the isolates are considered resistant strains according to EUCAST interpretive criteria for ceftazidime and the figures indicate the
percentage of strains in each quadrant. AVI, avibactam; CAZ, ceftazidime; S, susceptible; I, intermediate; R, resistant.
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